<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:9pt Arial, sans-serif; }
 .font2 { font:10pt Arial, sans-serif; }
 .font3 { font:27pt Arial, sans-serif; }
 .font4 { font:15pt Times New Roman, serif; }
 .font5 { font:22pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font2">07 September 2016</span></p>
<p><span class="font2">Isabella Y. Zhao, CFA</span></p>
<p><span class="font2">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font2">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font3">Investment Positives</span></p><a name="caption1"></a>
<h6><a name="bookmark0"></a><span class="font4" style="font-weight:bold;"><a name="bookmark1"></a>Dominant industry leader</span></h6>
<p><span class="font4">Sinopharm is the largest pharmaceutical distributor with a dominant market leadership (18.4% market share in 2015), far exceeding CR Pharma’s 10% and Shanghai</span></p>
<p><span class="font4">Pharma’s 8.6%. It has a truly nationwide pharmaceutical distribution network with total 241 logistics outlets covering 31 provinces, municipalities across China.</span></p>
<p><span class="font2" style="font-weight:bold;">Table 1: Distribution network comparison table 2015</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Company</span></p></td><td style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Ticker</span></p></td><td colspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">2015 Revenue (Milion)</span></p></td><td style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Growth (%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Gross</span></p>
<p><span class="font0" style="font-weight:bold;">Margin</span></p></td><td style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Main</span></p>
<p><span class="font0" style="font-weight:bold;">Distribution Aea</span></p></td><td style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">No. of Retail</span></p>
<p><span class="font0" style="font-weight:bold;">Outlets</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Sinopharm</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">1099</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Distribution</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">213,994</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">12.50%</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">8.20%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Country wide</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">3080</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Retail</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">8,715</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">47.70%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">Country wide</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">CR Pharma</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">Priv ate</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">Distribution</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">104,683</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">8.90%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">6.70%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">Country wide</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">702</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Retail</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">3,104</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">20.10%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">20.10%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">North and Eastern</span></p>
<p><span class="font1">China</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Shanghai</span></p>
<p><span class="font0" style="font-weight:bold;">Pharm</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">601607</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Distribution</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">93,717</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">14.30%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">6.10%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">North, East,</span></p>
<p><span class="font1">South China</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">1769</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Retail</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">4,795</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">42.00%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">16.00%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">East China</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Jointown</span></p>
<p><span class="font0" style="font-weight:bold;">Pharma</span></p>
<p><span class="font0" style="font-weight:bold;">(32.9%)</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">600998</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">Distribution</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">47,748</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">20.40%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">6.10%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">Country wide</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1">869</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Retail</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">984</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">32.9</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">17.90%</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">East, Central,</span></p>
<p><span class="font1">North China</span></p></td></tr>
</table>
<p><span class="font2">Source: China Pharmaceutical Commerce, JP Morgan</span></p>
<p><span class="font4" style="font-weight:bold;">Continuous market share gains with increasing industry consolidation </span><span class="font4">According to the China Association of Pharmaceutical Commerce, Sinopharm increased its market share in the pharmaceutical distribution market to 18.4% in 2015, up from merely 4.4% in 2003. The top 5 players accounted for over 40% in terms of revenue in 2015. We expect the leading players to have more than a 50% market share in China by 2020, still well below the normal 60-80% market share that the top three distributors have in more developed markets. More importantly, we believe recent government policies such as the new GSP (Good Standard Practice) regulations, un-announced inspections of pharmaceuticals and medical devices, “two invoices” system for distributors will force out smaller players from the industry, thus offering Sinopharm ample room to further gain market by acquiring smaller &amp;&nbsp;local players. According to management, Sinopharm will focus on the acquisition of retail businesses, i.e. direct-to-pharmacy, in-hospital drug stores, etc.</span></p>
<p><span class="font4">We expect Sinopharm will be able to raise its market share to 25% by 2020.</span></p>
<p><span class="font2">8</span></p>
</body>
</html>